High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
750.06M
+23.37%
1.050
+9.19%
764.10M
+3.96%
1.051
+1.07%
754.92M
+1.74%
1.219
+5.86%
Estimates Revision
The market is revising Downward the revenue expectations for Royalty Pharma plc (RPRX) for FY2025, with the revenue forecasts being adjusted by -0.61% over the past three months. During the same period, the stock price has changed by 4.66%.
Revenue Estimates for FY2025
Revise Downward
-0.61%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1.05%
In Past 3 Month
Stock Price
Go Up
+4.66%
In Past 3 Month
5 Analyst Rating
0Wall Street analysts forecast RPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPRX is 41.60 USD with a low forecast of 33.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
0Current: 34.560
Low
33.00
Averages
41.60
High
51.00
0Current: 34.560
Low
33.00
Averages
41.60
High
51.00
Morgan Stanley
Overweight
initiated
$51
2025-05-16
Reason
Morgan Stanley
Price Target
$51
2025-05-16
initiated
Overweight
Reason
Morgan Stanley resumed coverage of Royalty Pharma with an Overweight rating and $51 price target. The firm cites se the company's diversified portfolio and insulation from potential tariffs, coupled with a growth profile above the peer average, as positives.
Citigroup
Andrew Baum
Strong Buy
Maintains
$60 → $40
2024-10-25
Reason
Citigroup
Andrew Baum
Price Target
$60 → $40
2024-10-25
Maintains
Strong Buy
Reason
Goldman Sachs
Chris Shibutani
Strong Buy
Maintains
$50 → $51
2024-08-14
Reason
Goldman Sachs
Chris Shibutani
Price Target
$50 → $51
2024-08-14
Maintains
Strong Buy
Reason
Morgan Stanley
Terence Flynn
Buy
Maintains
$48 → $51
2024-07-11
Reason
Morgan Stanley
Terence Flynn
Price Target
$48 → $51
2024-07-11
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Royalty Pharma PLC (RPRX.O) is 7.14, compared to its 5-year average forward P/E of 10.78. For a more detailed relative valuation and DCF analysis to assess Royalty Pharma PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
10.78
Current PE
7.14
Overvalued PE
14.43
Undervalued PE
7.13
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
10.78
Current EV/EBITDA
8.38
Overvalued EV/EBITDA
13.04
Undervalued EV/EBITDA
8.52
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
6.19
Current PS
4.55
Overvalued PS
7.63
Undervalued PS
4.76
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 100.83% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
RPRX News & Events
Events Timeline
(ET)
2025-05-20
07:53:53
Royalty Pharma 12M share Spot Secondary priced at $33.25
2025-05-08 (ET)
2025-05-08
07:30:38
Royalty Pharma sees FY25 portfolio receipts $2.975B-$3.125B
2025-04-08 (ET)
2025-04-08
16:38:25
Royalty Pharma appoints Biohaven CEO Vlad Coric to board
Sign Up For More Events
Sign Up For More Events
News
Preview
4.5
06-12NASDAQ.COMAfter Hours Most Active for Jun 11, 2025 : PLTR, NVDA, AMZN, AAPL, RPRX, MCHPP
Preview
3.0
06-12CNBCA bullish breakout in this little-known pharma stock is forming, charts show
Preview
1.0
06-05Yahoo FinanceRoyalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Sign Up For More News
People Also Watch
FAQ
What is Royalty Pharma PLC (RPRX) stock price today?
What is Royalty Pharma PLC (RPRX)'s business?
What is the price predicton of RPRX Stock?
What is Royalty Pharma PLC (RPRX)'s revenue for the last quarter?
What is Royalty Pharma PLC (RPRX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Royalty Pharma PLC (RPRX)'s fundamentals?
How many employees does Royalty Pharma PLC (RPRX). have?